MRTX1133 was nominated as December 2021’s cover molecule by reviewers Joachim Rudolph and Julien Lefranc . MRTX1133 is a non-covalent inhibitor of KRASG12D that demonstrated tumor regression in a mouse xenograft model when dosed IP (maximum efficacy at 10-30 mg/kg, activity as low as 3 mg/kg). Joachim said, “The discovery of MRTX1133 deserves [...]
1 minute read
Feb. 9, 2022
MRTX1133: a Non-Covalent Inhibitor of KRASG12D
Mirati KRASG12D Inhibitor
reversible KRASG12D inhibitor preclinical efficacy in cancer model from SBDD around KRASG12C inhibitor MRTX1133 Mirati Therapeutics, San Diego, CA
Reviewer: